RxDoctor Payments Data

Sunil Sinha, MD

Clinical Cardiac Electrophysiology · Baltimore, MDNPI 1578595393

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,249 of the $8,884 with a category attached, or 92.9%. Johnson & Johnson accounts for 93.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $6,285 and has fallen 98.9% since, to $66 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in MD, where the typical reported total is $15,262.

$8,884in general payments, 2019–2025

Across 22 payments — averaging $403.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$8K
  • Biosense Webster, Inc.$231
  • Atricure, Inc.$141
  • Medtronic$96
  • Boston Scientific$36
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$28
  • plus $38 from 2 others

What the payments were for

  • Consulting fees$8,24993%
  • Food & beverage$6357%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,884 in reported general payments places this provider in the 35th percentile of 63 clinical cardiac electrophysiology providers in Maryland.

See all clinical cardiac electrophysiology providers in Maryland

Medicare billing

Part B allowed, 2024
$211,104
Medicare patients
967
Services billed
2,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$114,205
XareltoRivaroxaban79$109,690
MultaqDronedarone Hcl33$58,695
Dofetilide31$12,915
Propafenone Hcl ErPropafenone Hcl14$6,261
Amiodarone Hcl126$6,069
Flecainide Acetate57$2,522
Ranolazine ErRanolazine25$1,960
Metoprolol Succinate114$1,863
Digoxin32$1,148
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$986
Diltiazem 24hr ErDiltiazem Hcl15$436
Tiadylt ErDiltiazem Hcl15$431
Carvedilol37$339
Furosemide28$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$8,315$109,69079 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 63 clinical cardiac electrophysiology providers in Maryland.

Other clinical cardiac electrophysiology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →